<DOC>
	<DOCNO>NCT00031031</DOCNO>
	<brief_summary>The Kanglaite Injection ( KLT ) novel broad spectrum anti-cancer injection produce traditional Chinese medicinal herb ( Coix Seed ) . It approve China 1995 become popular anti-cancer drug China . In June 2001 , Phase I study KLT commence Huntsman Cancer Institute Salt Lake City , Utah , objectives 1 ) To determine maximum tolerate dose ( MTD ) safety profile KLT patient refractory solid tumor ; 2 ) To determine pharmacokinetics KLT patient refractory solid tumor ; 3 ) To gather preliminary efficacy data . The method test open-label , sequential cohort , dose-escalation study .</brief_summary>
	<brief_title>Kanglaite Injection Phase I Study</brief_title>
	<detailed_description />
	<criteria>Patients histological evidence malignancy become refractory standard therapy , effective standard therapy exist . Patients estimated lifeexpectancy least 3 month Patients Karnofsky Performance Score least 60 % Patients history congestive heart failure ( CHF ) , normal ejection fraction echocardiography Patients adequate renal hepatic function Patients adequate bone marrow status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>MTD</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Efficacy</keyword>
</DOC>